CD16 × IL-15 × Epcam TriKE, CD16 × IL-15 × CD133 TriKEs, and CD16 × IL-15 × CD133 × Epcam TetraKE are under investigation to treat colorectal cancer and have shown significantly enhanced cytokine secretion, NK cell proliferation, and lytic degranulation (108–110). This evidence concerns the gene IL15 and colorectal cancer.